CARDIAC PACEMAKER MARKET ANALYSIS

A cardiac pacemaker is a small-sized device that is implanted in the chest to control the slow heartbeat. The cardiac pacemaker implantation is carried out with a surgical procedure. There are three types of cardiac pacemakers such as single-chamber pacemaker, dual-chamber pacemaker, and biventricular pacemaker. Single chamber pacemaker is placed within the lower chamber or ventricle of the heart, whereas dual chamber pacemaker has two leads and are placed in the right atrium and right ventricle. Furthermore, biventricular pacemaker is used in cardiac resynchronization therapy to treat heart failure. Biventricular pacemaker sends electrical pulses to the right and left ventricles to pump. Moreover, pacemakers are implanted in two ways such as internal cardiac pacemaker, which is implanted within the body to send electrical impulses to regulate the heart rhythm. Another implanting procedure is external cardiac pacemaker, which is also known as an artificial pacemaker, and is an electrode-based medical device used for regulating the contractility of myocardiocytes, cells that are involved in cardiac remodeling for proper heart rate.

The global cardiac pacemaker market is estimated to be valued at US$ 4,547.8 Mn in 2022 and is expected to exhibit a CAGR of 3.3% over the forecast period (2022-2030).

Figure 1: Global Cardiac Pacemaker Market Share (%) Analysis, By Product Type, 2022

To learn more about this report, request a free sample copy

Increasing product approval by regulatory authorities is expected to drive the global cardiac pacemaker market growth over the forecast period.

Increasing product approval by regulatory authorities is expected to drive the global cardiac pacemaker market growth over the forecast period. For instance, on June 15, 2020, Medtronic plc., a medical device company announced that the company received CE mark by European Union (EU) for Micra AV Transcatheter Pacing System (TPS), a small pacemaker with features such as atriventricular (AV) synchrony. This device is indicated for treatment of patients with AV blocks, impaired heart chambers to provide electrical signals for proper functioning of heart.

Increasing inorganic activities among market players is expected to drive the global cardiac pacemaker market growth over the forecast period.

Increasing inorganic activities such as agreements, partnerships, and collaborations among market players is expected to drive the global cardiac pacemaker market growth over the forecast period. For instance, on December 17, 2021, LifeTech Scientific Corporation, a China-based company and manufacturer of interventional medical devices announced its extension of agreements with Medtronic plc. a medical devices company for  HeartTone domestic pacemaker project. This project agreement includes extension of project till 2028, where Medtronic will provide series of specialized technical consulting services.

Global Cardiac Pacemaker Market- Impact of the Coronavirus (COVID-19) Pandemic

The COVID-19 pandemic is expected to hamper the global cardiac pacemaker market growth, owing to its impact on cardiac surgeries.  For instance, in March 2022, according to a study published in the National Center for Biotechnology Information (NCBI) on the impact of the COVID pandemic on cardiac surgeries in the U.S. that ended in 2020, there was a 52.7% reduction in adult cardiac surgery volume and a 65.5% reduction in elective cases across the country. The first COVID-19 pandemic had the impact on the Mid-Atlantic area, which indicated a drop in overall case volume for cardiac surgeries, which was around 69.7% of population in mid-Atlantic region.

Global Cardiac Pacemaker Market– Restraints

Product recall for cardiac pacemakers by market players is expected to hamper the global cardiac pacemaker market over the forecast period. For instance, in August 2021, Boston Scientific, a of medical device manufacturing company announced recalling notice for pacemakers and cardiac resynchronization therapy pacemakers (CRT-Ps) due to the risk of transitioning to safety mode. Safety mode is intended to provide backup if the device is faulty. These pacemakers or cardiac resynchronization therapy pacemakers (CRT-Ps) belongs to Boston Scientific’s INGENIO product portfolio, which is used for patients who have low heart rates, and patients with moderate to severe heart failure, a condition where heart cannot pump enough blood as per requirement for patient.

Global Cardiac Pacemaker Market– Regional Analysis

On the basis of region, the global cardiac pacemaker market is segmented into North America, Latin America, Europe, Asia Pacific, Middle East, and Africa.

Among regions, North America is expected to hold a dominant position in the market during the forecast period, owing to increasing prevalence of heart diseases in the U.S. For instance, According to the Centers for Disease Control and Prevention (CDC), over 360,900 persons died in the United States in 2019 as a result of coronary heart disease, and around 18.2 million adults aged 20 and older had coronary artery disease (CAD), accounting for about 6.2 percent of the population. According to the same source, around 805,000 people in the United States suffer from heart attacks each year.

Figure 2: Global Cardiac Pacemaker Market Value (US$ Mn), by Region, 2022

To learn more about this report, request a free sample copy

Global Cardiac Pacemaker Market– Competitive Landscape

Major players operating in the global cardiac pacemaker market include Medtronic, Boston Scientific Corporation, Abbott, BIOTRONIK SE & Co. KG, Pacetronix, Lepu Medical Technology (Beijing)Co., Ltd. , LIVANOVA PLC, MEDICO S.R.L., OSCOR Inc., MicroPort Scientific Corporation, OSYPKA MEDICAL, and Vitatron Holding B.V.